It has been reported that type II membrane-bound glycoprotein FAP is not expressed in normal tissues but expressed in activated CAFs in the tumor stroma, and FAPα-expressing vaccines can inhibit the growth of 4T1 tumors (breast cancer) by killing CAFs by generating FAPα-specific cytotoxic T lymphocyte (CTL) responses [111]. Here, FAP is linked to breast cancer.